Estrogen therapy to treat retinopathy in newborn mice

Shi,Wenjing; Zhu,Li; Wang,Yuhuan; Hu,Baoyang; Xiao,Honglei; Zhou,Guoming; Chen,Chao

doi:10.3892/etm.2015.2554

Estrogen therapy to treat retinopathy in newborn mice

Authors:
- Wenjing Shi
- Li Zhu
- Yuhuan Wang
- Baoyang Hu
- Honglei Xiao
- Guoming Zhou
- Chao Chen
View Affiliations

Affiliations: Department of Neonatology, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Human Anatomy, Histology and Embryology, Fudan University, Shanghai 200032, P.R. China
Published online on: June 5, 2015 https://doi.org/10.3892/etm.2015.2554
Pages: 611-617

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to treat retinopathy of prematurity (ROP) with estrogen (E2) so as to elucidate the role of E2 in the pathogenesis of ROP. A total of 120 postnatal 7‑day‑old (P7) C57BL/6J mice were selected and raised in a high‑oxygen environment (75% oxygen) for 5 days, followed by 5 days in normal room air. Different doses of E2 or normal saline (NS) were injected intraperitoneally during different time‑periods, and the mice were divided into 14 groups according dose of E2 injection (0.5‑1.5 µg/0.05 ml) and dosing time. Blood vessel changes and hyperplasia were evaluated in flat‑mounted retina and retinal slices. All mice that were exposed to room air, whether they were administered E2 or NS, showed good vascular development in the flat‑mounted retina at P17. No increase in the number of endothelial cell nuclei in the new blood vessels was observed. In ascending order of E2 dose the numbers of cell nuclei were as follows: 0.18±0.129, 0.28±0.086 and 0.55±0.110. The number in the NS group was 2.12±0.373. When the results of the room‑air groups were compared with those of the hyperoxia groups, a highly significant difference was found in each comparison (P<0.0001). All mice showed varying degrees of neovascularization and vascular obstruction in the flat‑mounted retina at P17, and it was difficult to compare the blood vessels morphologically among these groups. The number of endothelial cell nuclei decreased following E2 injection, and the difference from the NS group exposed to hyperoxia was highly significant (P<0.0001). For all dose levels, the number of cell nuclei was the lowest when the drug was administered during P7‑16, and the difference from the other two time‑periods was statistically significant (P<0.05). When E2 was administered during P7‑16, the number of cell nuclei was 15.5±1.993 in the 0.5‑µg group, 14.23±2.49 in the 1.0‑µg group and 18.05±1.62 in the 1.5‑µg group. No significant difference was found among these three groups (P>0.05). In conclusion, E2 treatment during the development of retinopathy can improve symptoms in neonatal mice, suggesting that E2 plays an important role at the two initial stages in the pathogenesis of ROP. This may indicate new pharmacological measures to prevent and treat ROP.

View Figures

View References

1	Chen J and Smith LE: Retinopathy of prematurity. Angiogenesis. 10:133–140. 2007. View Article : Google Scholar : PubMed/NCBI
2	Li Z and Ni WJ: Advances of biological drugs for retinal neovascularization. Guo Ki Yan Ke Za Zhi. 7:1119–1123. 2007.(In Chinese).
3	No authors listed. An international classification of retinopathy of prematurity. Pediatrics. 74:127–133. 1984.PubMed/NCBI
4	No authors listed. An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol. 105:906–912. 1987. View Article : Google Scholar : PubMed/NCBI
5	Cryotherapy for Retinopathy of Prematurity Cooperative Group, . Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 106:471–479. 1988. View Article : Google Scholar : PubMed/NCBI
6	Cryotherapy for Retinopathy of Prematurity Cooperative Group, . Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol. 108:195–204. 1990. View Article : Google Scholar : PubMed/NCBI
7	Cryotherapy for Retinopathy of Prematurity Cooperative Group, . Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome - structure and function. Arch Ophthalmol. 108:1408–1416. 1990. View Article : Google Scholar : PubMed/NCBI
8	Cryotherapy for Retinopathy of Prematurity Cooperative Group, . Multicenter trial of cryotherapy for retinopathy of prematurity. 3 1/2-year outcome - structure and function. Arch Ophthalmol. 111:339–344. 1993. View Article : Google Scholar : PubMed/NCBI
9	Cryotherapy for Retinopathy of Prematurity Cooperative Group, . Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Arch Ophthalmol. 114:417–424. 1996. View Article : Google Scholar : PubMed/NCBI
10	Greven CM and Tasman W: Rhegmatogenous retinal detachment following cryotherapy in retinopathy of prematurity. Arch Ophthalmol. 107:1017–1018. 1989. View Article : Google Scholar : PubMed/NCBI
11	Ben-Sira I, Nissenkorn I, Weinberger D, Shohat M, Kremer I, Krikler R and Reisner SH: Long-term results of cryotherapy for active stages of retinopathy of prematurity. Ophthalmology. 93:1423–1428. 1986. View Article : Google Scholar : PubMed/NCBI
12	Quinn GE, Miller DL, Evans JA, Tasman WE, McNamara JA and Schaffer DB: Measurement of Goldmann visual fields in older children who received cryotherapy as infants for threshold retinopathy of prematurity. Arch Ophthalmol. 114:425–428. 1996. View Article : Google Scholar : PubMed/NCBI
13	Biglan AW, et al: Progress in ROP research. Chin J Med. 1:7–13. 1990.
14	Ma DH, Chen JK, Zhang F, Lin KY, Yao JY and Yu JS: Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res. 25:563–590. 2006. View Article : Google Scholar : PubMed/NCBI
15	Mintz-Hittner HA, Kennedy KA and Chuang AZBEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 364:603–615. 2011. View Article : Google Scholar : PubMed/NCBI
16	Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF and Campochiaro PA: Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology. 116:1748–1754. 2009. View Article : Google Scholar : PubMed/NCBI
17	Yatoh S, Kawakami Y, Imai M, Kozawa T, Segawa T, Suzuki H, Yamashita K and Okuda Y: Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation. 66:1519–1524. 1998. View Article : Google Scholar : PubMed/NCBI
18	Moshfeghi DM and Berrocal AM: Retinopathy of prematurity in the time of bevacizumab: Incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 118:1227–1228. 2011.PubMed/NCBI
19	O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
20	Suzuma K, Takagi H, Otani A, Oh H and Honda Y: Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol. 154:343–354. 1999. View Article : Google Scholar : PubMed/NCBI
21	Coughlin SR: Thrombin signaling and protease-activated receptors. Nature. 407:258–264. 2000. View Article : Google Scholar : PubMed/NCBI
22	Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD and Blake DA: Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci. 41:2378–2388. 2000.PubMed/NCBI
23	Lonchampt M, Pennel L and Duhault J: Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest Ophthalmol Vis Sci. 42:429–432. 2001.PubMed/NCBI
24	Falavarjani KG and Nguyen QD: Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye(Lond). 27:787–794. 2013.PubMed/NCBI
25	Hoerster R, Muether P, Dahlke C, Mehler K, Oberthür A, Kirchof B and Fauser S: Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 91:e74–e75. 2013. View Article : Google Scholar : PubMed/NCBI
26	Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, Liao JK and De Caterina R: Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res. 87:19–25. 2000. View Article : Google Scholar : PubMed/NCBI
27	Ma X, Bi H, Qu Y, Xie X and Li J: The contrasting effect of estrogen on mRNA expression of VEGF in bovine retinal vascular endothelial cells under different oxygen conditions. Graefes Arch Clin Exp Ophthalmol. 249:871–877. 2011. View Article : Google Scholar : PubMed/NCBI
28	Thompson LP, Pinkas G and Weiner CP: Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation. 102:445–451. 2000. View Article : Google Scholar : PubMed/NCBI
29	Suzuma I, Mandai M, Takagi H, Suzuma K, Otani A, Oh H, Kobayashi K and Honda Y: 17 Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci. 40:2122–2129. 1999.PubMed/NCBI
30	Miyamoto N, Mandai M, Takagi H, Suzuma I, Suzuma K, Koyama S, Otani A, Oh H and Honda Y: Contrasting effect of estrogen on VEGF induction under different oxygen status and its role in murine ROP. Invest Ophthalmol Vis Sci. 43:2007–2014. 2002.PubMed/NCBI
31	Takeyama J, Suzuke T, Inoue S, Kaneko C, Nagura H, Harada N and Sasano H: Expression and cellular localization of estrogen receptors and in the human fetus. J Clin Endocrinol Metab. 86:2258–2262. 2001. View Article : Google Scholar : PubMed/NCBI
32	Gruber CJ, Tschugguel W, Schneeberger C and Huber JC: Production and actions of estrogens. N Engl J Med. 346:340–352. 2002. View Article : Google Scholar : PubMed/NCBI
33	Huppmann S, Römer S, Altmann R, Obladen M and Berns M: 17beta-estradiol attenuates hyperoxia-induced apoptosis in mouse C8-D1A cell line. J Neuro Res. 86:3420–3426. 2008. View Article : Google Scholar
34	Morles DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK and Schnaper HW: Molecular and cellular cardiology: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 91:755–763. 1995. View Article : Google Scholar : PubMed/NCBI
35	Shi WJ, Chen C, Zhou GM, Hu BY and Xiao HL: The role of vascular endothelial growth factor, fibroblast growth factor-2 and estrogen receptor in the pathogenesis of retinopathy of neonatal mice. Fudan Xue Bao Yi Xue Ban Bian Ji Wei Yuan Hui. 34:228–232. 2007.(In Chinese).
36	Trotter A, Maier L, Grill HJ, Kohn T, Heckmann M and Pohlandt F: Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J Clin Endocrinol Metab. 84:4531–4535. 1999. View Article : Google Scholar : PubMed/NCBI
37	Trotter A, Bokelmann B, Sorgo W, Bechinger-Kornhuber D, Heinemann H, Schmücker G, Oesterle M, Köhntop B, Brisch KH and Pohlandt F: Follow-up examination at the age of 15 months of extremely preterm infants after postnatal estradiol and progesterone replacement. J Clin Endocrinol Metab. 86:601–603. 2001. View Article : Google Scholar : PubMed/NCBI
38	Trotter A, Maier L, Kohn T, Böhm W and Pohlandt F: Growth of the uterus and mammary glands and vaginal cytologic features in extremely premature infants with postnatal replacement of estradiol and progesterone. Am J Obstet Gynecol. 186:184–188. 2002. View Article : Google Scholar : PubMed/NCBI
39	McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Müller KH, Sharkey AM and Smith SK: Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 98:482–489. 1996. View Article : Google Scholar : PubMed/NCBI
40	Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, Simpkins JW, Inokuchi K and Koulen P: Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Vesl-1 L/Homer 1c immunoreactive synaptic connections. Invest Ophthalmol Vis Sci. 44:3155–3162. 2003. View Article : Google Scholar : PubMed/NCBI
41	Xu J and Su H: Body surface area calculation method for humans and animalsPharmacological Experiments. Yuanpei Zhang: Beijing Publication Group; Beijing: pp. 2411996
42	Yuen KK and Kahn HA: The association of femal hormones with blindness from diabetic retinopathy. Am J Ophthalmol. 81:820–822. 1976. View Article : Google Scholar : PubMed/NCBI
43	Porter JC: Hormonal regulation of breast development and activity. J Invest Dermatol. 63:85–92. 1974. View Article : Google Scholar : PubMed/NCBI